Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Silverberg, Jonathan, I [2 ]
Calimlim, Brian M. [3 ]
Liu, Yingyi [3 ]
Platt, Andrew [3 ]
Thyssen, Jacob P. [4 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, Washington, DC USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
upadacitinib; dupilumab; atopic dermatitis; skin clearance; EASI;
D O I：
10.1093/bjd/ljac140.047
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
355
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    de Bruin-Weller, Marjolein
    Calimlim, Brian M.
    Hu, Xiaofei
    Ofori, Sarah A.
    Platt, Andrew M.
    Teixeira, Henrique D.
    Eyerich, Kilian
    Thyssen, Jacob P.
    DERMATITIS, 2024, 35 (03) : 266 - 274
  • [42] 413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)
    Lio, Peter
    Eichenfield, Lawrence F.
    Marcoux, Danielle
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Raymundo, Eliza M.
    Gamelli, Amy E.
    Grada, Ayman
    Hu, Xiaofei
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [43] Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up)
    Simpson, Eric L.
    Costanzo, Antonio
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Chu, Alvina D.
    Wu, Tianshuang
    Eyerich, Kilian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II30 - II31
  • [44] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
    Blauvelt, Andrew
    Ladizinski, Barry
    Prajapati, Vimal H.
    Laquer, Vivian
    Fischer, Alison
    Eisman, Samantha
    Hu, Xiaofei
    Wu, Tianshuang
    Calimlim, Brian M.
    Kaplan, Blair
    Liu, Yingyi
    Teixeira, Henrique D.
    Liu, John
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
  • [45] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Silverberg, Jonathan I.
    Deleuran, Mette
    Gold, Linda S.
    Bunick, Christopher G.
    Hijnen, Dirk Jan
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Platt, Andrew M.
    Grada, Ayman
    Hu, Xiaofei
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
  • [46] DISCONTINUATION OF TOPICAL CORTICOSTEROIDS IN UPADACITINIB-TREATED PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS FROM THE AD UP PHASE 3 TRIAL
    Reich, Kristian
    Boguniewicz, Mark
    Kabashima, Kenji
    Barbarot, Sebastien
    Girolomoni, Giampiero
    Mendes-Bastos, Pedro
    Gamelli, Amy
    Liu, Yingyi
    Teixeira, Henrique
    Armstrong, April
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 61 - 61
  • [47] Discontinuation of topical corticosteroids in upadacitinib-treated patients with moderate-to-severe atopic dermatitis: analysis from the AD Up phase III trial
    Reich, K.
    Boguniewicz, M.
    Kabashima, K.
    Barbarot, S.
    Girolomoni, G.
    Mendes-Bastos, P.
    Gamelli, A.
    Liu, Y.
    Teixeira, H.
    Armstrong, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E118
  • [48] EFFICACY AND SAFETY OF DUPILUMAB TREATMENT UP TO 1 YEAR IN INFANTS AND PRESCHOOL CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Paller, Amy S.
    Siegfried, Elaine C.
    Xiao, Jing
    Prescilla, Randy
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [49] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Herranz, Pedro
    de la Cueva, Pablo
    Rodriguez Marco, Ainara
    Worrell, Richard
    Shumel, Brad
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
  • [50] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Roh, Joo Young
    Park, Chun Wook
    Kim, Kyu Han
    Lee, Joo Hee
    Sun, Xian
    Rossi, Ana B.
    Shumel, Brad
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53
12345